The antiviral protein cyanovirin-N: The current state of its production and applications

Applied Microbiology and Biotechnology

Volumn 86, Issue 3, 2010, Pages 805-812

  Xiong, Sheng ^a   Fan, Jun ^a   Kitazato, Kaio ^b  

^a JINAN UNIVERSITY   (China)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cyanovirin N; Gp120 binding; Heterologous production; Human immunodeficiency virus; Microbicide; Pharmacological evaluation

Indexed keywords

ANTI-HIV; ANTIVIRAL PROTEIN; ARTIFICIAL PRODUCTION; DIFFERENT MECHANISMS; HETEROLOGOUS PRODUCTION; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HUMAN IMMUNODEFICIENCY VIRUS; IN-VITRO; LARGE-SCALE PRODUCTION; MEDICAL USE; MICROBICIDES; POTENT ACTIVITY; STRUCTURAL FEATURE; STRUCTURAL MECHANISMS; TRIAL AND ERROR;

DEVELOPING COUNTRIES; DISEASES; PROTEINS;

VIRUSES;

ACTINOHIVIN; ANTIVIRUS AGENT; CYANOVIRIN N; GRIFFITHSIN; LECTIN; MICROBICIDE; PRO 2000; SCYTOVIRIN; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY; BIOTECHNOLOGY; CYANOBACTERIUM; DISEASE CONTROL; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN; VACCINE;

ANTIVIRAL ACTIVITY; CELL TYPE; CLINICAL TRIAL; COMMENSAL; CYTOTOXICITY; DRUG FORMULATION; DRUG INHIBITION; DRUG TARGETING; ESCHERICHIA COLI; EUKARYOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MITOGENESIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SHORT SURVEY; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; CYANOBACTERIA; HIV; HUMANS; RECOMBINANT PROTEINS;

CYANOBACTERIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77950629248     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-010-2470-1     Document Type: Short Survey

References (45)

1. Balzarini J (2007) Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir Chem Chemother 18:1-11 (Pubitemid 46426933)
2. Balzarini J, Van Damme L (2007) Microbicide drug candidates to prevent HIV infection. Lancet 369:787-797 (Pubitemid 46335821)
3. Barrientos LG, Louis JM, Botos I, Mori T, Han Z, O'Keefe BR, Boyd MR, Wlodawer A, Gronenborn AM (2002) The domainswapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures. Structure 10:673-686 (Pubitemid 34518710)
4. Barrientos LG, Matei E, Lasala F, Delgado R, Gronenborn AM (2006) Dissecting carbohydrate-cyanovirin-N binding by structureguided mutagenesis: functional implications for viral entry inhibition. Protein Eng Des Sel 19:525-535 (Pubitemid 44950458)
5. Bewley CA, Gustafson KR, Boyd MR, Covell DG, Bax A, Clore GM, Gronenborn AM (1998) Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol 5:571-578 (Pubitemid 28317733)
6. Botos I, O'Keefe BR, Shenoy SR, Cartner LK, Ratner DM, Seeberger PH, Boyd MR, Wlodawer A (2002) Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem 277:34336-34342
7. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH 2nd, Buckheit RW Jr, Nara PL, Pannell LK, Sowder RC 2nd, Henderson LE (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virusinactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41:1521-1530 (Pubitemid 27289680)
8. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90:234-243
9. Cohen J (2009) HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine "success". Science 326:652-653
10. Colgan R, Atkinson CJ, Paul M, Hassan S, Drake PM, Sexton AL, Santa-Cruz S, James D, Hamp K, Gutteridge C, Ma JK (2010) Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals. Transgenic Res (in press)
11. Colleluori DM, Tien D, Kang F, Pagliei T, Kuss R, McCormick T, Watson K, McFadden K, Chaiken I, Buckheit RW Jr, Romano JW (2005) Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif 39:229-236 (Pubitemid 40084609)
12. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA (2000) Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74:4562-4569 (Pubitemid 30237881)
13. Drake PM, Barbi T, Sexton A, McGowan E, Stadlmann J, Navarre C, Paul MJ, Ma JK (2009) Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco. FASEB J 23:3581-3589
14. Fischetti L, Barry SM, Hope TJ, Shattock RJ (2009) HIV-1 infection of human penile explant tissue and protection by candidate microbicides. Aids 23:319-328
15. Fromme R, Katiliene Z, Fromme P, Ghirlanda G (2008) Conformational gating of dimannose binding to the antiviral protein cyanovirin revealed from the crystal structure at 1.35 A resolution. Protein Sci 17:939-944 (Pubitemid 351629588)
16. Gao X, Chen W, Guo C, Qian C, Liu G, Ge F, Huang Y, Kitazato K, Wang Y, Xiong S (2010) Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His- SUMO fusion. Appl Microbiol Biotechnol 85(4):1051-1060
17. Giomarelli B, Provvedi R, Meacci F,Maggi T,Medaglini D, PozziG,Mori T, McMahon JB, Gardella R, Boyd MR (2002) The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. Aids 16:1351-1356 (Pubitemid 34722066)
18. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA (2008) Whither or wither microbicides? Science 321:532-534
19. Gustafson KR, Sowder RC 2nd, Henderson LE, Cardellina JH 2nd, McMahon JB, Rajamani U, Pannell LK, Boyd MR (1997) Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun 238:223-228 (Pubitemid 27453305)
20. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J (2006) Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 281:25177-25183 (Pubitemid 44401904)
21. Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368:145-154 (Pubitemid 47599570)
22. Huskens D, Vermeire K, Profy AT, Schols D (2009) The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res 84:38-47
23. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP, Xu Q (2006) Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 50:3250-3259 (Pubitemid 44527495)
24. Liu Y, Carroll JR, Holt LA, McMahon J, Giomarelli B, Ghirlanda G (2009) Multivalent interactions with gp120 are required for the anti-HIV activity of cyanovirin. Biopolymers 92:194-200
25. Mori T, Shoemaker RH, McMahon JB, Gulakowski RJ, Gustafson KR, Boyd MR (1997) Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. Biochem Biophys Res Commun 239:884-888 (Pubitemid 27504197)
26. Mori T, Gustafson KR, Pannell LK, Shoemaker RH, Wu L, McMahon JB, Boyd MR (1998) Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif 12:151-158 (Pubitemid 28360439)
27. Mori T, Barrientos LG, Han Z, Gronenborn AM, Turpin JA, Boyd MR (2002) Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. Protein Expr Purif 26:42-49 (Pubitemid 35307485)
28. Morris GC, Lacey CJ (2010) Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 23:57-63
29. Ndesendo VM, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC (2008) A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/ AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 9:505-520
30. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR (2003) Potent antiinfluenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 47:2518-2525 (Pubitemid 36919454)
31. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE (2009) Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 106:6099-6104
32. Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JK (2006) Transgenic plant production of cyanovirin-N, an HIV microbicide. FASEB J 20:356-358 (Pubitemid 46671170)
33. Sexton A, Harman S, Shattock RJ, Ma JK (2009) Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 23:3590-3600
34. Shattock RJ, Moore JP (2003) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1:25-34
35. Shattock R, Solomon S (2004) Microbicides-aids to safer sex. Lancet 363:1002-1003
36. Shenoy SR, O'Keefe BR, Bolmstedt AJ, Cartner LK, Boyd MR (2001) Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther 297:704-710
37. Tanaka H, Chiba H, Inokoshi J, Kuno A, Sugai T, Takahashi A, Ito Y, Tsunoda M, Suzuki K, Takenaka A, Sekiguchi T, Umeyama H, Hirabayashi J, Omura S (2009) Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci USA 106:15633-15638
38. Terpe K (2006) Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 72:211-222 (Pubitemid 44273045)
39. Tiwari V, Shukla SY, Shukla D (2009) A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion. Antiviral Res 84:67-75
40. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR (2003) Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 19:535-541 (Pubitemid 36900571)
41. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20:11-18 (Pubitemid 38147172)
42. UNAIDS (2008). Report on the global AIDS epidemic 2008. In: Unaids. org. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008-Global-report.asp. Accessed 6 Nov 2008
43. Vorontsov II, Miyashita O (2009) Solution and crystal molecular dynamics simulation study of m4-cyanovirin-N mutants complexed with di-mannose. Biophys J 97:2532-2540
44. Yang F, Bewley CA, Louis JM, Gustafson KR, Boyd MR, Gronenborn AM, Clore GM, Wlodawer A (1999) Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol 288:403-412 (Pubitemid 29221810)
45. Zappe H, Snell ME, Bossard MJ (2008) PEGylation of cyanovirin-N, an entry inhibitor of HIV. Adv Drug Deliv Rev 60:79-87 (Pubitemid 350181168)